GTBP Stock Summary and Trading Ideas (GT Biopharma | NASDAQ:GTBP)

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

GT Biopharma trades on the NASDAQ stock market under the symbol GTBP.

As of October 21, 2026, GTBP stock price declined to $5.41 with 165,448 million shares trading.

GTBP has a beta of 1.71, meaning it tends to be more sensitive to market movements. GTBP has a correlation of 0.04 to the broad based SPY ETF.

GTBP has a market cap of $9.76 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, GTBP traded as high as $266.50 and as low as $4.91.

The top ETF exchange traded funds that GTBP belongs to (by Net Assets): VXF.

GTBP has underperformed the market in the last year with a price return of -70.4% while the SPY ETF gained +16.3%. GTBP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.5% and -15.1%, respectively, while the SPY returned +4.4% and -0.8%, respectively.

GTBP support price is $6.80 and resistance is $7.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GTBP shares will trade within this expected range on the day.